Skip to main content
. 2021 May 29;9(6):618. doi: 10.3390/biomedicines9060618

Table 2.

List of recurrent somatic SNVs affecting uAUG and aTIS codons selected for experimental analysis.

Gene Symbol RefSeq ID Genomic
Position
Codon
Variant
Functional
Effect
Type of Cancer (% of Patients) uORF Size in bp # of uAUG
in TLS
uStop to CDS Distance (bp) Kozak Context TV
with uORF
ASNS
NM_001352496.2
chr7:
97928300
AUG.2 > GUG uAUG > aTIS BRCA (0.4) 303 4 74 ++ 1/7
BAGE2
NM_182482.2
chr21:
10413537
CUG.1 > CCG loss of aTIS COAD (2.1); LUAD (1.4); LAML (1.3); SKCM (0.9); PRAD (0.6); BRCA (1.0) 78 3 126 + 5/5
BAGE2
NM_182482.2
chr21:
10413594
UUG.1 > GUG syn aTIS SKCM (1.9); BRCA (1.3);
PRAD (0.8); COAD (0.6)
105 3 41 5/5
CFH
NM_000186.3
chr1:
196651949
UUG.3 > UUU/
GUG.5 > UUG
loss of aTIS/
syn aTIS
BRCA (2.2) 39/138 1 132/31 + 2/2
CHCHD2 NM_001320327.1 chr7:
56106490
AUC.1 > AUU loss of aTIS SKCM (8.1) 63 1 16 2/2
DIS3L
NM_133375.4
chr15:
66294990
AUG.1 > AUU uAUG > aTIS SKCM (0.9) 27 2 83 ++ 10/13
ESRRG
NM_001438.4
chr1:
216723407
GUG.1 > GGG loss of aTIS BRCA (3.0) 39 1 70 + 4/20
FANK1
NM_145235.5
chr10: 125896600 AGG.2 > ACG syn aTIS COAD (1.6) 105 0 44 + 2/3
FRG2C
NM_001124759.3
chr3:
75664297
ACG.2 > AUG aTIS > uAUG LAML (6.0); SKCM (2.1);
LUAD (0.7); PRAD (0.4)
21 3 63 + 1/1
HLA-DRB1 NM_002124.3 chr6:
32589821
AUG.1 > AUA/
GUG.1 > AUG
uAUG > aTIS/
aTIS > uAUG
LAML (1.3); LUAD (1.1); PRAD (0.6); BRCA (0.6);
SKCM (0.4)
36/30 1 45/49 + 2/4
HLA-DRB1 NM_002124.3 chr6:
32589752
CUG.1 > CUC loss of GTG COAD (1.6); SKCM (1.3);
LUAD (0.5); BRCA (0.2)
66 1 −13 + 2/4
HLA-DRB1 NM_002124.3 chr6:
32589795
CUG.6 > GUG syn aTIS LAML (2.7); LUAD (0.3);
BRCA (0.3)
813 1 −801 2/4
NDST3
NM_004784.3
chr4:
118053872
AUG.4 > AUU uAUG > aTIS SKCM (1.1) 21 4 20 + 1/1
PJA2
NM_014819.4
chr5:
109383504
UUG.2 > UUU loss of aTIS LAML (2.0); LUAD (1.4);
BRCA (1.3); PRAD (0.4)
15 0 58 + 1/1
PRKCQ NM_001282644.2 chr10:
6515109
UUG.2 > UUU loss of aTIS LAML (3.4); BRCA (2.8);
LUAD (1.8); PRAD (0.6);
SKCM (0.4)
156 1 −74 + 4/7
PRMT8
NM_019854.5
chr12:
3491521
UUG.5 > GUG syn aTIS BRCA (1.7) 1290 1 −1185 ++ 1/2
RBBP4
NM_001135256.1
chr1:
32651992
AUG.3 > UUG uAUG > aTIS LAML (2.0) 12 3 −1 1/3
ROPN1
NM_017578.4
chr3:
123980570
GUG.6 > GGG loss of aTIS BRCA (2.2); LAML (1.3) 54 4 36 1/3
SETD4
NM_001007261.2
chr21:
36058888
AUG.1 > UUG uAUG > aTIS LAML (1.3) 174 3 −8 + 4/4
SYNPR
NM_144642.5
chr3:
63443357
GUG.2 > GGG loss of aTIS BRCA (8.2); COAD (4.4);
LAML (3.4)
30 1 57 1/2
TEDDM1
NM_172000.4
chr1:
182400520
AUG.2 > UUG uAUG > aTIS LAML (2.7) 39 2 −4 + 1/1
TMIGD3 NM_001081976.2 chr1:
111563996
UUG.1 > GUG syn aTIS LAML (4.0); LUAD (0.7);
PRAD (0.4); BRCA (0.3)
138 0 −94 + 2/3
TNFSF8
NM_001244.3
chr9:
114930326
AUG.6 > GUG uAUG > aTIS LAML (1.4) 147 6 −147 + 2/2

# = number; negative values in “uStop to CDS distance in bp” indicate overlap of the uORF into the CDS; The Kozak sequences surrounding the uORF initiation sites are classified as strong (++) if both core bases (underlined) match, adequate (+) if one of the core bases matches or weak (−) if none of the core bases match with the optimal Kozak consensus sequence (GCCRCCaugG).